(Q50723945)

18 March 2018

title

Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. (English)

1 reference

18 March 2018

1 reference

Karyn M Maclennan

1

1 reference

18 March 2018

Andrew Boshier

series ordinal

2

1 reference

18 March 2018

Lynda V Wilton

series ordinal

3

1 reference

18 March 2018

Saad A W Shakir

series ordinal

4

1 reference

18 March 2018

publication date

1 July 2006

1 reference

18 March 2018

published in

BJU International

1 reference

18 March 2018

volume

98

1 reference

18 March 2018

issue

1

1 reference

18 March 2018

page(s)

125-131

1 reference

18 March 2018

Erectile dysfunction: management update

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

Epidemiology of Erectile Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

Coronary artery risk factors in patients with erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

Sexual dysfunction and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

Oral treatment of erectile dysfunction with apomorphine SL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

Tolerability and safety of apomorphine SL (Ixense (TM) ).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

Key issues from the clinical trials of apomorphine SL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06253.X

10.1111/J.1464-410X.2006.06253.X

21 January 2018

Identifiers

DOI

1 reference

18 March 2018

PubMed ID

16831156

1 reference

18 March 2018